ArticleTherapeutic advances in hematology2020

One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.

Hubert Schrezenmeier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.